Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification and optimization of peptide inhibitors to block VISTA/PSGL-1 interaction for cancer immunotherapy

8 Aug 2023

Abstract excerpt

Developing new therapeutic agents for cancer immunotherapy is highly demanding due to the low response ratio of PD-1/PD-L1 blockade in cancer patients. Here, we discovered that the novel immune checkpoint VISTA is highly expressed on a variety of tumor-infiltrating immune cells, especially myeloid derived suppressor cells (MDSCs) and CD8+ T cells. Then, peptide C1 with binding affinity to VISTA was developed by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Immune cells in cancer
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37969728
DOI: 10.1016/j.apsb.2023.08.003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification and optimization of peptide inhibitors to block VISTA/PSGL-1 interaction for cancer immunotherapyPMID 37969728Read ↗

PSGL-1 Immune Checkpoint Inhibition for CD4+ T Cell Cancer Immunotherapy.Semantic proximity Read ↗

Novel multivalent S100A8 inhibitory peptides attenuate tumor progression and metastasis by inhibiting the TLR4-dependent pathwaySemantic proximity Read ↗

Targeting KRASG12V mutations with HLA class II-restricted TCR for the immunotherapy in solid tumors.Semantic proximity Read ↗

Identification of novel KRASG12D neoantigen specific TCRs and a strategy to eliminate off-target recognitionSemantic proximity Read ↗

Peptide Phage Display: Opportunities for Development of Personalized Anti-Cancer StrategiesSemantic proximity Read ↗

VISTA: A Promising Target for Cancer Immunotherapy?Semantic proximity Read ↗

KRASG12V/HLA-A*02:01-targeted chimeric antigen receptor T cells exhibit potent preclinical activity against solid tumors.Semantic proximity Read ↗

Targeting tumor tolerance: A new hope for pancreatic cancer therapy?Semantic proximity Read ↗

Anti-PD-1-iRGD Peptide Conjugate Boosts Antitumor Efficacy via Engagement Augmentation and Penetration Enhancement of T cellsSemantic proximity Read ↗

Insilico Identification of MHC displayed Tumor Associated Peptides in Ovarian Cancer for Multi-Epitope Vaccine ConstructSemantic proximity Read ↗

AI/ML-Assisted Computational Design and Immunoinformatics Evaluation of a Multi-Epitope Vaccine Targeting Podoplanin in <i>Glioblastoma Multiforme</i>Semantic proximity Read ↗

In situ vaccination using unique TLR9 ligand K3-SPG induces long-lasting systemic immune response and synergizes with systemic and local immunotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.